xeconatyxex.blogspot.com
Scientists at M. D. Anderson in Houstobn and AstraZeneca in Wilmington will work togetherd to better understand how chemotherapies cause peripheral nerve dysfunctions that cancaused numbness, tingling and severe pain. Such side the organization said, often limit optimal therapeutifc dosing incancer treatments. The scientists' hope is theitr research will lead to new treatments to prevent which would extend the therapeutiv value ofexisting chemotherapies, and to the development of new chemotherapiew with less severe pain-related side effects. M.D. Andersobn and AstraZeneca first established an alliancr in 2006 to accelerat e the evaluation and approvalof anti-cancer drugs.
"We hope the insights we gain fromthis [expanded] alliance will ultimatelt lead to new treatment options that will improve the qualitg of life for cancer patients," said Bob vice president for neuroscience at AstraZeneca. of Exton initiated a multicentet phase-II study of its Morab-009 monoclonal antibody product, in combinatioj with the chemotherapydrug gemcitabine, as a treatmen for patients with pancreatic cancer. Morphotek expects to enrolol up to 152 patients in the clinical study, which is being conducted at clinical centerds in North America, South America and Europe ...
of Horshamn has started treating patients ina phase-k human safety study of NUC its experimental treatment for chronichepatitiss B virus infection. The company's new drug candidate is an RNA interference-baserd therapeutics that is designed to turn off a gene associaterd withthe disease. The goal of the stud is to enroll 15 patients atthree U.S. clinicalp sites and two sites in Easter nEurope ... Blue Bell-based received Food and Drug Administrationh approval to begin testingthe company's lead anti-inflammatorh compound, VGX-1027, which is being development as a potential treatmentf for rheumatoid arthritis and Type 1 diabetes ...
announceed positive preclinical test resultx for Trodusquemine as a treatmentgfor type-2 diabetes. The Plymouth Meeting biopharmaceuticall company is already testing Trodusqueminrein phase-I clinical trials as a treatment for Jack Armstrong, Genaera's president and CEO, said the companu has amended its investigational new drug applicatiomn to pursue both indications and "maximizwe the therapeutic potential" of the Genaera expects to pursue type-2 diabetes as its lead indicatioh for Trodusquemine in phase-II clinical trials ...
of Yardle plans to follow up two positivre midstage testings of its experimental canine allergudrug Promist-VEL502 with a "confirmatory" study this year and a pivotak late-stage test next year. The product incorporatess Velcera's patented Promist drug-delivery syste that allows the drug to be formulatefd as a metered dose liquid mist that can be sprayef inside the oral cavity ofa dog'a mouth. The delivery system avoids the need to get pets to swallosw pillsor liquids. Dennis the company's president and CEO, said Velcera is on trackl to receive product approval for the allergy a major cause of skin in2012 ...
Wayne-based received FDA approvapl to marketthe company'xs VascuView Visual Ultrasound System for use with assister vascular access procedures. The producgt provides physicians with a largse image display of targeted vessel s andsurrounding anatomy. The marketin g clearance for VascuViewwas Escalon's third FDA approvapl in the last six weeks.
No comments:
Post a Comment